BR0213237A - Derivados de ácido [[2-(amino-3,4-dioxo-1-ciclobuten-1-il) amino] alquila] para o tratamento de dor - Google Patents

Derivados de ácido [[2-(amino-3,4-dioxo-1-ciclobuten-1-il) amino] alquila] para o tratamento de dor

Info

Publication number
BR0213237A
BR0213237A BR0213237-0A BR0213237A BR0213237A BR 0213237 A BR0213237 A BR 0213237A BR 0213237 A BR0213237 A BR 0213237A BR 0213237 A BR0213237 A BR 0213237A
Authority
BR
Brazil
Prior art keywords
alkyl
amino
dioxo
treatment
pain
Prior art date
Application number
BR0213237-0A
Other languages
English (en)
Inventor
Michael Richard Brandt
Margaret Maria Zaleska
John Allen Moyer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0213237A publication Critical patent/BR0213237A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DERIVADOS DE áCIDO [[2-(AMINO-3,4-DIOXO-1CICLOBUTEN-1-IL) AMINO] ALQUILA] PARA O TRATAMENTO DE DOR". A presente invenção refere-se a um método para o tratamento de dor em um mamífero que inclui a administração, a um mamífero em necessidade deste tratamento, de uma quantidade eficaz para o tratamento de dor de um composto de fórmula (I): onde R^ 1^ é H, alquila ou fenilalquila; R^ 2^ é H, alquila, alquenila ou fenilalquila; ou R^ 1^ e R^ 2^ compreendidos juntos como Z são -CH~ 2~C-H~ 2~-,-CH~ 2~C (R^ 6^) (R^ 7^) CH~ 2~- ou -CH~ 2~C(R^ 8^) (R^ 9^)-C (R^ 10^) (R^ 11^) CH~ 2~-, onde R^ 6^, R^ 8^ e R^ 10^ são, independentemente, H, alquila ou hidroxila e R^ 7^, R^ 9^ e R^ 11^ são, independentemente, H ou alquila; A é alquileno ou alquenileno; X é CO~ 2~R^ 3^, p (O) (OR^ 4^) (OR^ 5^) , 3, 5-dioxo-1,2,4-oxadiazolidin-2-ila ou 5-tetrazolila, no qual R^ 3^, R^ 4^ e R^ 5^ São, independentemente, H ou alquila, ou uma composição farmacêutica para o tratamento da dor, contendo uma quantidade eficaz para o tratamento da dor do composto de fórmula (I).
BR0213237-0A 2001-10-10 2002-10-09 Derivados de ácido [[2-(amino-3,4-dioxo-1-ciclobuten-1-il) amino] alquila] para o tratamento de dor BR0213237A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32824501P 2001-10-10 2001-10-10
PCT/US2002/032252 WO2003031416A2 (en) 2001-10-10 2002-10-09 [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain

Publications (1)

Publication Number Publication Date
BR0213237A true BR0213237A (pt) 2004-09-28

Family

ID=23280159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213237-0A BR0213237A (pt) 2001-10-10 2002-10-09 Derivados de ácido [[2-(amino-3,4-dioxo-1-ciclobuten-1-il) amino] alquila] para o tratamento de dor

Country Status (27)

Country Link
US (2) US7098200B2 (pt)
EP (1) EP1434588B1 (pt)
JP (1) JP4350512B2 (pt)
KR (1) KR100922703B1 (pt)
CN (1) CN100448449C (pt)
AR (1) AR036764A1 (pt)
AT (1) ATE515266T1 (pt)
AU (1) AU2009201746A1 (pt)
BR (1) BR0213237A (pt)
CA (1) CA2461348C (pt)
CY (1) CY1111909T1 (pt)
DK (1) DK1434588T3 (pt)
EA (1) EA009993B1 (pt)
ES (1) ES2367356T3 (pt)
HK (1) HK1064609A1 (pt)
HU (1) HUP0401773A3 (pt)
IL (2) IL161275A0 (pt)
MX (1) MXPA04003354A (pt)
NO (1) NO20041378L (pt)
NZ (1) NZ532159A (pt)
PL (1) PL368863A1 (pt)
PT (1) PT1434588E (pt)
SI (1) SI1434588T1 (pt)
TW (1) TWI321472B (pt)
UA (1) UA78529C2 (pt)
WO (1) WO2003031416A2 (pt)
ZA (1) ZA200403406B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1562567T (pt) * 2002-11-22 2017-08-24 Gruenenthal Gmbh Combinação de analgésicos selecionados e inibidores da cox-ii
ATE481103T1 (de) * 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
US20050004079A1 (en) * 2003-04-09 2005-01-06 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GT200400213A (es) 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
CA2583114A1 (en) * 2004-10-08 2006-04-20 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and method of making them
CA2697739A1 (en) * 2007-08-27 2009-03-05 Wyeth Llc Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect
DK3566703T3 (da) * 2009-02-13 2021-07-05 Allergan Inc Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
WO2010108063A1 (en) 2009-03-19 2010-09-23 Wyeth Llc Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof
CA2856507C (en) 2011-11-21 2017-03-21 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
WO2015149066A1 (en) * 2014-03-28 2015-10-01 University Of Virginia Patent Foundation General anesthetics that are not neurotoxic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
DK124393D0 (da) 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
AT400440B (de) * 1993-12-06 1995-12-27 Vianova Kunstharz Ag Verfahren zur herstellung von wasserverdünnbaren lackbindemitteln und deren verwendung
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
UA52698C2 (uk) * 1996-10-04 2003-01-15 Х. Луннбек А/С Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
AU746119B2 (en) 1997-08-01 2002-04-18 Wyeth Process for the preparation of (2-((8,9)- dioxo-2,6-diazabicyclo (5.2.0)-non-1(7)-en-2-yl)-ethyl) phosphonic acid
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US20030158254A1 (en) 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain

Also Published As

Publication number Publication date
CA2461348A1 (en) 2003-04-17
WO2003031416A3 (en) 2003-08-14
HUP0401773A3 (en) 2005-06-28
DK1434588T3 (da) 2011-08-15
US7759346B2 (en) 2010-07-20
ZA200403406B (en) 2007-04-25
US20060205696A1 (en) 2006-09-14
NZ532159A (en) 2006-02-24
PT1434588E (pt) 2011-09-05
JP4350512B2 (ja) 2009-10-21
PL368863A1 (en) 2005-04-04
IL161275A0 (en) 2004-09-27
KR20050034604A (ko) 2005-04-14
WO2003031416A2 (en) 2003-04-17
EA009993B1 (ru) 2008-06-30
JP2005508950A (ja) 2005-04-07
HK1064609A1 (en) 2005-02-04
CA2461348C (en) 2011-02-15
MXPA04003354A (es) 2004-09-28
CN100448449C (zh) 2009-01-07
NO20041378L (no) 2004-05-28
EP1434588A2 (en) 2004-07-07
ATE515266T1 (de) 2011-07-15
US7098200B2 (en) 2006-08-29
KR100922703B1 (ko) 2009-10-22
EA200400523A1 (ru) 2004-08-26
HUP0401773A2 (hu) 2005-01-28
CN1568189A (zh) 2005-01-19
AU2009201746A1 (en) 2009-05-28
ES2367356T3 (es) 2011-11-02
AR036764A1 (es) 2004-09-29
EP1434588B1 (en) 2011-07-06
TWI321472B (en) 2010-03-11
US20030114444A1 (en) 2003-06-19
UA78529C2 (en) 2007-04-10
SI1434588T1 (sl) 2011-10-28
CY1111909T1 (el) 2015-11-04
IL161275A (en) 2009-09-01

Similar Documents

Publication Publication Date Title
BRPI0417687A (pt) derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BR0315580A (pt) Derivados de metileno uréia
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
BR0215429A (pt) Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente
BR0214986A (pt) S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
BR0212455A (pt) Composto, formulação farmacêutica, combinação, uso de um composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, e, processo para preparar um composto
BRPI0510666A (pt) compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BRPI0509512A (pt) método de tratar esquizofrenia e/ou anormalidades glicorregulatórias
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
BR0213237A (pt) Derivados de ácido [[2-(amino-3,4-dioxo-1-ciclobuten-1-il) amino] alquila] para o tratamento de dor
BR9810911A (pt) Composto, e, processo para tratar câncer em um mamìfero
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
BRPI0405657A (pt) Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
ATE270550T1 (de) Wirkstoff zum schutz für organ oder gewebe
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
BRPI0417902A (pt) piperazinas úteis no tratamento da dor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.